All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Incyte Corp.
Enrolment target
12
Start
11 May 2023
What is this study about?
Assessment of AEs and SAEs reported in participants continuing to receive itacitinib.
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (6)
- —Italy
- —Spain
- —Austria
- —Germany
- —Belgium
- —Greece
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.